Remedium Lifecare Ltd
Incorporated in 1988, Remedium Lifecare Ltd is in the business of trading in Advanced Pharmaceutical Intermediates and other pharma products
- Market Cap ₹ 112 Cr.
- Current Price ₹ 1.27
- High / Low ₹ 31.5 / 0.80
- Stock P/E
- Book Value ₹ 0.48
- Dividend Yield 0.00 %
- ROCE 1.39 %
- ROE 3.55 %
- Face Value ₹ 1.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 51.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 1.13%
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.12.4 Cr.
- Company has high debtors of 969 days.
- Working capital days have increased from 21.4 days to 68.6 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 4 | 1 | 0 | 0 | 3 | 90 | 505 | 510 | 4,040 | 222 | 163 | |
1 | 2 | 4 | 1 | 0 | 0 | 2 | 89 | 503 | 502 | 4,006 | 224 | 170 | |
Operating Profit | 0 | -0 | -0 | -0 | 0 | -0 | 0 | 1 | 2 | 8 | 34 | -2 | -6 |
OPM % | 3% | -8% | -8% | -7% | 0% | -44% | 14% | 1% | 0% | 2% | 1% | -1% | -4% |
0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 11 | 12 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 5 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit before tax | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 7 | 50 | 4 | 1 |
Tax % | 50% | 21% | 0% | 0% | 0% | 100% | 24% | 26% | 29% | 27% | 35% | 58% | |
0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 33 | 2 | -0 | |
EPS in Rs | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.06 | 0.37 | 0.02 | 0.00 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 59% |
5 Years: | 138% |
3 Years: | -24% |
TTM: | -96% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 40% |
3 Years: | 12% |
TTM: | -274% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 0% |
3 Years: | -29% |
1 Year: | -96% |
Return on Equity | |
---|---|
10 Years: | 41% |
5 Years: | 48% |
3 Years: | 51% |
Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 10 | 40 |
Reserves | -0 | -1 | -1 | -1 | -1 | -1 | -0 | 0 | 1 | 7 | 33 | 3 |
1 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 58 | 1,141 | |
1 | 3 | 2 | 0 | 0 | 0 | 1 | 24 | 219 | 1,144 | 1,847 | 355 | |
Total Liabilities | 6 | 6 | 5 | 3 | 3 | 4 | 4 | 39 | 224 | 1,154 | 1,948 | 1,540 |
2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
4 | 4 | 5 | 3 | 3 | 4 | 4 | 38 | 224 | 1,154 | 1,948 | 1,540 | |
Total Assets | 6 | 6 | 5 | 3 | 3 | 4 | 4 | 39 | 224 | 1,154 | 1,948 | 1,540 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | -1 | 0 | -0 | -0 | -0 | -10 | 11 | 20 | -74 | -1,079 | ||
0 | 1 | 0 | 0 | 1 | -0 | -0 | -0 | -0 | 0 | 0 | ||
-0 | -0 | 0 | 0 | 0 | 0 | 10 | -11 | -0 | 54 | 1,078 | ||
Net Cash Flow | -0 | 0 | 0 | -0 | 1 | -0 | -0 | 1 | 20 | -20 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 120 | 341 | 265 | 596 | 2,117 | 319 | 189 | 96 | 46 | 123 | 83 | 969 |
Inventory Days | 1,129 | 243 | 78 | 0 | 0 | 5 | 12 | 455 | ||||
Days Payable | 102 | 438 | 129 | 62 | 65 | 542 | ||||||
Cash Conversion Cycle | 1,147 | 146 | 214 | 596 | 2,117 | 319 | 189 | 96 | 46 | 67 | 30 | 882 |
Working Capital Days | 566 | 107 | 200 | 524 | 2,159 | 4,745 | 323 | 54 | 2 | -8 | 4 | 69 |
ROCE % | 1% | 1% | 0% | 1% | 1% | 11% | 7% | 18% | 103% | 100% | 1% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1d - Submission of newspaper publication intimating members for holding ensuing AGM for 2024-25 through VC/OAVM
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2d - Q1 FY26 PAT ₹464.88 lakh; EBITDA +508%; oversubscribed ₹47.88 crore rights issue.
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 13 Aug
-
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
13 Aug - Appointment of two non-executive independent directors approved via postal ballot on 12 Aug 2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
11 Aug - Q1 FY26 PAT ₹464.88L, doubling FY25 profit; plans R&D expansion and global growth.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
Company does trading and sale of API intermediates (KSMs & CRMs) and various other raw materials used in API trading to innovator and generic pharmaceutical players in Domestic and International markets